Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs
08 Enero 2024 - 1:00AM
Orion and Glykos announce research collaboration and licensing
agreement to develop next-generation ADCs
ORION CORPORATION PRESS RELEASE 8 JANUARY 2024 at 09.00 EET
Orion and Glykos announce research collaboration and
licensing agreement to develop next-generation ADCs
Orion Corporation and Glykos Finland Oy announced today
that they have entered into a research collaboration and licensing
agreement to develop next-generation antibody-drug conjugates
(ADCs).
Under the agreement, Orion gains access to Glykos’ proprietary
ADC technologies, initiating an ADC program with the potential for
expansion into two additional programs in the future. Orion will be
responsible for the target selection, research, development, and
commercialization of up to three next-generation ADCs, with a focus
on solid tumors.
Glykos is eligible for milestone payments related to signing of
the agreement, target selection and sales milestones. Glykos is
also entitled to receive royalties on commercial sales generated
from the three ADC programs.Outi Vaarala, Senior
Vice President, Innovative Medicines and R&D, Orion, said:
“Collaboration with Glykos and possibility to utilize their ADC
technology complements nicely our research portfolio in oncology
and is yet another demonstration of our will to develop new
treatment options for cancer patients with unmet needs.”
Juhani Saarinen, CEO of Glykos, said: "The
acknowledgment of our ADC technology by an esteemed pharmaceutical
company like Orion is a strong statement to the transformative
potential of these technologies in enhancing the therapeutic index
of ADCs. We look forward to partnering with Orion and believe that
with their expertise on cancer therapies and robust clinical
pipeline, this partnership can deliver innovative medicines for
cancer patients.”
About OrionOrion is a globally operating
Finnish pharmaceutical company – a builder of well-being. We
develop, manufacture and market human and veterinary
pharmaceuticals and active pharmaceutical ingredients. Orion has an
extensive portfolio of proprietary and generic medicines and
self-care products. The core therapy areas of our pharmaceutical
R&D are oncology and pain. Proprietary products developed by
Orion are used to treat cancer, neurological diseases and
respiratory diseases, among others. Orion's net sales in 2022
amounted to EUR 1,341 million and the company had about 3,500
employees at the end of the year. Orion's A and B shares are listed
on Nasdaq Helsinki.
About GlykosGlykos, focusing on antibody-drug
conjugates (ADCs), is dedicated to revolutionizing cancer
treatment. Glykos' proprietary hydrophilic payload and linker
technology addresses ADC limitations, offering benefits of high
efficacy, increased tolerability, excellent pharmacokinetics, and
optimized conjugation with any monoclonal antibody. Focused on
expanding the therapeutic index, we aim to extend survival and
enhance the quality of life for cancer patients. For more
information, please visit
www.glykos.fi. Contact
person:Terhi Ormio, VP, CommunicationsOrion
Corporationtel. +358 50 966 4646e-mail:
terhi.ormio@orion.fi
Publisher:Orion
CorporationCommunicationsOrionintie 1A, FI-02200 Espoo,
Finlandwww.orion.fi
Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De May 2023 a May 2024